Novartis Oncology Alliances

At Novartis Oncology, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer. As part of our commitment to patients and healthcare professionals, we have developed Alliance sites with patient support materials, educational materials, clinical trial, information and more.

Check below for informaiton on these alliances:

CML Alliance™
Chronic Myeloid Leukemia

When patients have Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML), healthcare professionals want to provide access to the full potential of advanced care for Ph+ CML. Now this information is available – visit CML Alliance™.

GIST Alliance™
Global Intestinal Stromal Tumours

Novartis introduces GIST Alliance™, a unique support program designed to help healthcare professionals optimize outcomes in Gastrointestinal Stromal Tumor (GIST) patients.

GISTs are currently the most common mesenchymal tumors of the gastrointestinal tract, with an estimated 3300 to 6000 new cases reported each year in the United States.^1,2 Approximately 2500 of these cases are metastatic at diagnosis.³

NET Alliance™
Neuroendocrine Tumor

Neuroendocrine tumors, also known as NETs, are an uncommon type of cancer that are sometimes referred to as carcinoid. The NET community was created to help patients and caregivers better understand NETs and connect with one another. If you or someone you know has a neuroendocrine tumor (NET) – click here for the NET Alliance™.

REFERENCES:

1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol Mech Dis. 2008;3:557-586.
2. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5(suppl2):S1–S29.
3. Griffin JM, St Amand M, Demetri GD. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin J Oncol Nurs. 2005;9(2):161-169.